drugset / Trial / NCT05601466
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Phase 1
Terminated
3 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Hangzhou Qihan Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML). The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Timeline
- Start
- 2022-03-26
- Primary completion
- 2023-04-11
- Completion
- 2023-04-11
Outcome
Outcome not reported
Stopped: “It did not reach the expected results of clinical trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QN-023a | Cell therapy | — | — |
| Background | Cyclophosphamid | Unknown | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |